2013 Press Releases

2015 | 2014 | 2013 | 2012 | 2011
Keyword Search
 
DateTitle 
11/20/13New Clinical Data on Urologix’ In-Office BPH Therapies Highlighted at Recent AUA Regional Meetings
... 
Printer Friendly Version
10/30/13Urologix Sponsors Residency Education at the Western AUA Meeting
... 
Printer Friendly Version
10/29/13Urologix Reports Fiscal Year 2014 First Quarter Results
Executive Summary First quarter revenue totaled $3.8 million, down 4.8% year-over-year. Reaffirms fiscal year 2014 total revenue guidance in the range of $15 million to $17 million. MINNEAPOLIS, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fiscal year 2014 first quarter ended September 30, 2013. First quarter fisca... 
Printer Friendly Version
10/23/13Urologix to Host Its Fiscal Year 2014 First Quarter Conference Call
MINNEAPOLIS, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX) will host a conference call to present fiscal year 2014 first quarter results on Tuesday, October 29, 2013 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-866-318-8617 and enter the Participant Passcode 50249354 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief... 
Printer Friendly Version
10/07/13Urologix Sponsors Physician Education at the North Central AUA Meeting
Urologix will host a hands-on workshop on Wednesday October 9th at the upcoming North Central Section of the AUA featuring advancements in BPH In-Office Therapy. MINNEAPOLIS, Minn., Oct 07, 2013 (GLOBE NEWSWIRE via COMTEX) -- via PRWEB - Urologix, Inc. (OTCQB:ULGX), the market leader for In-Office BPH Therapy, will host a hands-on workshop at the upcoming 87th Annual Meeting of the North Central Section of the AUA which is being held at the Ritz Carlton in Naples, Florida from October 8-12... 
Printer Friendly Version
09/30/13Urologix to Have National Presence at Upcoming AARP Life@50+ Event
Urologix, the market leader for In-Office BPH Therapy, will be sponsoring the educational session - Living With Frequent Urination? - Learn About Enlarged Prostate Solutions at the upcoming AARP "Life@50+" National Event and Expo in Atlanta. MINNEAPOLIS, Minn., Sep 30, 2013 (GLOBE NEWSWIRE via COMTEX) -- via PRWEB - Urologix, Inc. (OTCQB:ULGX) will have a national presence at the upcoming AARP "Life@50+" National Event and Expo being hosted in Atlanta at the Georgia World Congress Center f... 
Printer Friendly Version
08/26/13Urologix Applauds Research on Cost of BPH to Healthcare System
Study looks beyond the already significant cost of drug therapy and examines previously unpublished trends in emergency room visits by US males diagnosed with BPH. MINNEAPOLIS, Minn., Aug 26, 2013 (GLOBE NEWSWIRE via COMTEX) -- via PRWEB - Urologix, Inc. (OTC:ULGX) applauds the recent clinical article by Dr. Khurshid Roghmann et al, "Incidence and treatment patterns in males presenting with lower urinary tract symptoms to the emergency department in the United States" published in the June... 
Printer Friendly Version
08/20/13Urologix Reports Fourth Quarter and Fiscal Year 2013 Results
Executive Summary Fiscal year 2013 revenue totaled $16.6 million in-line with the Company's fiscal year guidance range of $16.0 million to $17.0 million. Fourth quarter revenue totaled $4.2 million, up 2.5% sequentially. Completed restructuring of $7.5 million to settle outstanding liabilities related to the Prostiva license. Introduces fiscal year 2014 total revenue guidance in the range of $15 million to $17 million. MINNEAPOLIS, Aug. 20, 2013 (GLOBE NEWSWIRE) ... 
Printer Friendly Version
08/14/13Urologix to Host Its Fourth Quarter and Full Fiscal Year 2013 Conference Call
MINNEAPOLIS, Aug. 14, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTC:ULGX) will host a conference call to present fourth quarter and full fiscal year 2013 results on Tuesday, August 20, 2013 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-877-703-6103 and enter the Participant Passcode 11902670 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet... 
Printer Friendly Version
07/01/13Urologix Announces Restructuring of Payment Obligations to Medtronic and Reports Preliminary Fiscal Year 2013 Revenue and Cash Results
MINNEAPOLIS, July 1, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office BPH therapy, announces the restructuring of payment obligations to Medtronic related to the licensing agreement with Medtronic for the Prostiva® Radio Frequency (RF) Therapy System and reports preliminary revenue and cash results for its fourth quarter and fiscal year 2013 ended June 30, 2013. Restructuring of Payment Obligations to Medtronic The terms of the restructuring agreem... 
Printer Friendly Version
06/05/13Urologix to Transfer From NASDAQ to the OTCQB Marketplace
MINNEAPOLIS, June 5, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, announced today that its Board of Directors has authorized the transfer of the Company's common stock from The NASDAQ Capital Market ("NASDAQ") to OTC Markets Group's OTCQB Marketplace ("OTCQB"). Urologix expects that its stock will begin trading on the OTCQB under the ticker symbol "ULGX" effective June 7, 2013. As of that date, investors and other interested parties will ... 
Printer Friendly Version
05/29/13Urologix In-Office BPH Therapy Featured on The Balancing Act on Lifetime Television
... 
Printer Friendly Version
05/02/13Urologix Brings Hands-On BPH Workshop to 2013 AUA Annual Meeting
... 
Printer Friendly Version
05/01/13Urologix Reports Fiscal Year 2013 Third Quarter Results and Reaffirms Annual Guidance
Third Quarter Summary Third quarter revenue of $4.1 million Quarter-end cash balance of $5.1 million Guidance for fiscal year 2013 revenue reaffirmed at $16.0 million to $17.0 million MINNEAPOLIS, May 1, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, today reported financial results for its fiscal year third quarter ended March 31, 2013. Third quarter fiscal year 2013 revenue totaled $4.1 million, down 6.3% seq... 
Printer Friendly Version
04/25/13Urologix to Host Its Fiscal Year 2013 Third Quarter Conference Call
MINNEAPOLIS--(BUSINESS WIRE)--Apr. 25, 2013-- Urologix®, Inc. (Nasdaq: ULGX) will host a conference call to present fiscal year 2013 third quarter results on Wednesday, May 1, 2013 at 4:00 p.m. CT, following the Company’s post-market press release on the same day. On the day of the call, please dial 1-877-299-4454 and enter the Participant Passcode 88115737 at least 10 minutes prior to the call. The conference call will be broadcast live over the Interne... 
Printer Friendly Version
04/17/13Urologix Receives Extension From NASDAQ to Regain Compliance With Listing Requirements
MINNEAPOLIS, April 17, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, announced today that the NASDAQ Hearings Panel (the "Panel") of The NASDAQ Stock Market LLC ("NASDAQ") has granted the Company's request for a further extension to regain compliance with the listing requirements of the NASDAQ. As previously reported, the Company's stock was subject to delisting due to the Company's failure to comply with the $1.00 minimum bid price re... 
Printer Friendly Version
04/15/13Urologix Announces Entry into Social Media
... 
Printer Friendly Version
04/08/13Urologix Announces Important Milestone in Prostiva(R) RF Therapy Licensing Agreement
MINNEAPOLIS, April 8, 2013 (GLOBE NEWSWIRE) -- Urologix, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, today announced that it has reached an important milestone in its licensing agreement with Medtronic for the Prostiva RF Therapy System. In accordance with the terms of the agreement, Urologix has become the licensed manufacturer for the Prostiva RF Therapy System, taking manufacturing and regulatory responsibility for the product line. This milestone represents an impo... 
Printer Friendly Version
03/12/13Urologix Announces BPH Presentation at the Southeastern AUA Section Meeting
... 
Printer Friendly Version
02/05/13Urologix Reports Fiscal Year 2013 Second Quarter Results and Reaffirms Annual Guidance
Executive Summary Second quarter revenue reported at $4.4 million, up 9.7% sequentially. Guidance for fiscal year 2013 revenue reaffirmed at $16.0 million to $17.0 million. MINNEAPOLIS, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, today reported financial results for its fiscal year second quarter ended December 31, 2012. Second quarter fiscal year 2013 revenue totaled $4.4 million, up 9.7% sequentially ... 
Printer Friendly Version
01/30/13Urologix Names Greg Fluet as New CEO
MINNEAPOLIS, Jan. 30, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, announced today that its Board of Directors has appointed Greg Fluet as the company's Chief Executive Officer, effective immediately. He has also been elected to the Company's Board of Directors. Mr. Fluet joined Urologix as Executive Vice President and Chief Operating Officer in July 2008 and served most recently as the Company's interim CEO since November 2012.   "Th... 
Printer Friendly Version
01/30/13Urologix to Host Its Fiscal Year 2013 Second Quarter Conference Call
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 30, 2013-- Urologix®, Inc. (Nasdaq:ULGX) will host a conference call to present fiscal year 2013 second quarter results on Tuesday, February 5, 2013 at 4:00 p.m. CT, following the Company’s post-market press release on the same day. On the day of the call, please dial 1-866-578-5788 and enter the Participant Passcode 18011408 at least 10 minutes prior to the call. The conference call will be broadcast live over the ... 
Printer Friendly Version
01/29/13Urologix Receives NASDAQ Notification Related to Minimum Bid Price Requirement
MINNEAPOLIS, Jan. 29, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, announced today that it received a letter from The NASDAQ Stock Market LLC ("NASDAQ") stating that the Company has not regained compliance with the minimum bid price requirement of Rule 5550(a)(2) within the 180 calendar day compliance period that ended on January 22, 2013 and that the Company's common stock is scheduled to be delisted from The Nasdaq Capital Market as of ... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Urologix, Inc. has a press release. Just enter your e-mail address and click Submit.